Abstract
The impacts of marine-derived n-3 polyunsaturated fatty acids (n-3 PUFAs) on cardiovascular risk are not well known. We conducted this meta-analysis to determine the effects of n-3 PUFAs on cardiovascular outcomes and cardiovascular risk markers in patients with impaired glucose metabolism (IGM). We searched PUBMED, EMBASE, The Cochrane Library and reference lists of relevant papers for high quality randomized controlled trials comparing dietary intake of n-3 PUFAs with placebo in IGM patients. Data was extracted and quality assessed independently by two reviewers. Authors were contacted for missing information. Overall estimates were calculated using a random-effects model or a fixed-effects model, and the possibility of publication bias was examined using a funnel plot. Subgroup analyses were conducted to explore the association between the risk markers and study characteristics. Our meta-analysis included 19 studies, 24,788 patients. Compared with placebo, n-3 PUFAs had no statistically significant reduce effect on cardiovascular mortality, major cardiovascular events, all-cause mortality or composite endpoint of all-cause mortality or hospitalization for cardiovascular cause, however it can significantly reduce the level of...Continue Reading
References
Jul 1, 1992·Archives of Internal Medicine·J D NeatonD Wentworth
Aug 1, 1990·Diabetes Care·T J HendraJ S Yudkin
Jan 1, 1995·Diabetes Care·W A MorganJ Rosenstock
Jan 1, 1993·Diabetologia·G E McVeighJ R Hayes
May 1, 1993·Diabetes Care·H T WesterveldJ D Banga
Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Apr 5, 1996·Atherosclerosis·L T McGrathG E McVeigh
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Oct 6, 1997·BMJ : British Medical Journal·M R TramèrH J McQuay
Sep 28, 2002·Diabetes Care·Martin PetersenPeter Marckmann
Nov 22, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A P Simopoulos
Apr 2, 2003·Circulation·Frank B HuJoAnn E Manson
Mar 1, 2007·European Journal of Clinical Nutrition·I L MostadV Grill
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Oct 19, 2007·Journal of Cardiovascular Medicine·Roberto MarchioliGianni Tognoni
Nov 13, 2008·Diabetologia·R R HolmanUNKNOWN Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group
May 19, 2009·Atherosclerosis·Shinichi OikawaUNKNOWN JELIS Investigators, Japan
Jun 23, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Sh PooyaF Toorang
Jul 11, 2009·Expert Review of Cardiovascular Therapy·Roberto MarchioliUNKNOWN GISSI-HF Investigators
Jan 15, 2010·The American Journal of Clinical Nutrition·Alin StirbanDiethelm Tschoepe
Feb 4, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·C-Y WongH-F Tse
Oct 12, 2010·The New England Journal of Medicine·Daan KromhoutUNKNOWN Alpha Omega Trial Group
Nov 10, 2010·Circulation·Bernhard RauchUNKNOWN OMEGA Study Group
Dec 1, 2010·BMJ : British Medical Journal·Pilar GalanUNKNOWN SU.FOL.OM3 Collaborative Group
Nov 24, 2011·Diabetes Care·Daan KromhoutErik J Giltay
Sep 13, 2012·JAMA : the Journal of the American Medical Association·Evangelos C RizosMoses S Elisaf
Citations
Sep 24, 2015·International Journal of Molecular Sciences·Hanne K MaehreKarl-Erik Eilertsen
Oct 4, 2016·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G ColussiL A Sechi
Nov 8, 2016·European Journal of Pharmacology·Rayan Khaddaj-MallatÉric Rousseau
Jul 19, 2018·The Cochrane Database of Systematic Reviews·Asmaa S AbdelhamidLee Hooper
Dec 7, 2018·The Cochrane Database of Systematic Reviews·Asmaa S AbdelhamidLee Hooper
Oct 24, 2018·Nutrients·Ewa Sokoła-WysoczańskaBożena Patkowska-Sokoła
Mar 3, 2020·The Cochrane Database of Systematic Reviews·Asmaa S AbdelhamidLee Hooper
Apr 4, 2020·Current Pharmaceutical Design·Kazuo Yamagata